TY  - JOUR
AU  - Stanisavljević, Nataša
AU  - Stojanovich, Ljudmila
AU  - Đoković, Aleksandra
AU  - Todić, Brankica
AU  - Dopsaj, Violeta
AU  - Saponjski, Jovica
AU  - Saponjski, Dušan
AU  - Marković, Olivera
AU  - Belizna, Cristina
AU  - Zdravković, Marija
AU  - Marisavljević, Dragomir
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4310
AB  - Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (p < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (p < 0.001, p = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (p < 0.001, p = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, p < 0.001) and to hsCRP (ρ 0.181, p = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, p = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients
VL  - 23
IS  - 20
DO  - 10.3390/ijms232012309
ER  - 

@article{
author = "Stanisavljević, Nataša and Stojanovich, Ljudmila and Đoković, Aleksandra and Todić, Brankica and Dopsaj, Violeta and Saponjski, Jovica and Saponjski, Dušan and Marković, Olivera and Belizna, Cristina and Zdravković, Marija and Marisavljević, Dragomir",
year = "2022",
abstract = "Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (p < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (p < 0.001, p = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (p < 0.001, p = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, p < 0.001) and to hsCRP (ρ 0.181, p = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, p = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients",
volume = "23",
number = "20",
doi = "10.3390/ijms232012309"
}

Stanisavljević, N., Stojanovich, L., Đoković, A., Todić, B., Dopsaj, V., Saponjski, J., Saponjski, D., Marković, O., Belizna, C., Zdravković, M.,& Marisavljević, D.. (2022). Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients. in International Journal of Molecular Sciences
MDPI., 23(20).
https://doi.org/10.3390/ijms232012309

Stanisavljević N, Stojanovich L, Đoković A, Todić B, Dopsaj V, Saponjski J, Saponjski D, Marković O, Belizna C, Zdravković M, Marisavljević D. Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients. in International Journal of Molecular Sciences. 2022;23(20).
doi:10.3390/ijms232012309 .

Stanisavljević, Nataša, Stojanovich, Ljudmila, Đoković, Aleksandra, Todić, Brankica, Dopsaj, Violeta, Saponjski, Jovica, Saponjski, Dušan, Marković, Olivera, Belizna, Cristina, Zdravković, Marija, Marisavljević, Dragomir, "Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients" in International Journal of Molecular Sciences, 23, no. 20 (2022),
https://doi.org/10.3390/ijms232012309 . .